Welcome to our dedicated page for Acrivon Therapeutics news (Ticker: ACRV), a resource for investors and traders seeking the latest updates and insights on Acrivon Therapeutics stock.
Acrivon Therapeutics, Inc. develops precision oncology medicines using its proprietary Generative Phosphoproteomics AP3 platform for drug design and predictive clinical development. The company’s recurring news centers on ACR-368, also known as prexasertib, a CHK1/2 inhibitor being developed with the ACR-368 OncoSignature assay for endometrial cancer, as well as ACR-2316, a WEE1/PKMYT1 inhibitor, and ACR-6840, a CDK11 development candidate.
Company updates commonly cover clinical and preclinical oncology data, scientific meeting presentations, FDA Fast Track and Breakthrough Device designations tied to ACR-368 and its assay, financial results, equity award disclosures, and the company’s internal CLIA-certified laboratory for patient testing and companion diagnostic development.
Acrivon Therapeutics, Inc. (Nasdaq: ACRV) has announced the pricing of its initial public offering (IPO), offering 7,550,000 shares at $12.50 each, targeting gross proceeds of about $99.4 million. A concurrent private placement of 400,000 shares will occur with existing stockholder Chione Limited. The IPO is set to begin trading on Nasdaq on November 15, 2022, closing on November 17, 2022, pending customary conditions. Acrivon is focused on precision oncology treatments backed by its proprietary AP3 platform, and its lead candidate ACR-368 is in a Phase 2 trial.